Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications-Reference-Cited by-同舟云学术

Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications

Published:2024-06-26 Issue:8 Volume:20 Page:959-970
ISSN:1744-666X
Container-title:Expert Review of Clinical Immunology
language:en
Short-container-title:Expert Review of Clinical Immunology

Author:

Sposito Marco¹,Eccher Serena¹,Pasqualin Luca¹,Scaglione Ilaria Mariangela¹,Avancini Alice¹²,Tregnago Daniela¹,Trestini Ilaria³,Insolda Jessica¹,Bonato Adele⁴,Ugel Stefano⁵^ORCID,Derosa Lisa⁶⁷,Milella Michele¹,Pilotto Sara¹^ORCID,Belluomini Lorenzo¹^ORCID

Affiliation:

1. Section of Oncology, Department of Engineering for Innovation Medicine (DIMI), University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy

2. Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

3. Dietetic Service, Hospital Medical Direction, University and Hospital Trust (AOUI) of Verona, Verona, Italy

4. Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy

5. Immunology Section, University Hospital and Department of Medicine, University of Verona, Verona, Italy

6. INSERM U1015 Gustave Roussy Cancer Campus, Villejuif Cedex, Villejuif, France

7. Faculté de Médicine, Université Paris-Saclay, Le Kremlin-Bicetre, France

Funder

not funded

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1744666X.2024.2372327

Reference95 articles.

1. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey

2. Molecular pathology of non‐small cell carcinoma

3. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

4. Novel ALK inhibitors in clinical use and development

5. ALK Inhibitors, Resistance Development, Clinical Trials